Accessibility Menu
Cardio Diagnostics logo

Cardio Diagnostics(NASDAQ) CDIO

Market Cap$4.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-99%
5 YearN/A
1 Year-58%
1 Month-13%
$1.75
+0.00%
+0.00Today
Cardio Diagnostics last closing stock price
MetricPriceDate
Last closeUSD 1.662026-08-06
Cardio Diagnostics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.73%USD 1.572026-07-30
1 month-13.09%USD 1.912026-07-07
3 month-9.29%USD 1.832026-05-08
Year to date-38.75%USD 2.712025-12-31
1 year-57.87%USD 3.942025-08-06
3 year-94.3%USD 29.102023-08-07
Since inception-99.44%USD 294.602022-01-14

Cardio Diagnostics Financials at a Glance

Market Cap

$4.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$16.57K

Net Income (TTM)

-$6.65M

EPS (TTM)

-$3.38

P/E Ratio

-0.49

Dividend

$0.00

Beta (Volatility)

1.16 (Average)

Price

$1.75

Volume

4,386.993

Open

$1.57

Previous Close

$1.66

Daily Range

$1.57 - $1.78

52-Week Range

$0.97 - $7.91

Estimated Earnings Date

Aug 13, 2026

CDIO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cardio Diagnostics

Cardio Diagnostics helps doctors and patients assess heart disease risk using blood tests. Its main products give early warnings about heart problems. These tests aim to support better health decisions for people at risk.

Lab Coats and Algorithms: What Cardio Diagnostics Sells

  • Coronary Heart Disease Tests: Epi+Gen CHD and PrecisionCHD are blood tests that estimate heart disease risk; 100% of revenue comes from these.
  • Research Tools: CardioInnovate360 supports drug discovery for heart disease, used by researchers and pharmaceutical companies.
  • Risk Intelligence Platform: HeartRisk is a software platform that helps organizations analyze and manage heart disease risk in groups.

Growth Spurts and Strategic Moves

  • Launched PrecisionCHD in March 2023 and CardioInnovate360 in May 2023.
  • Introduced HeartRisk platform in February 2024 to expand digital offerings.
  • Expanded sales team in late 2024 to target healthcare providers and employers.
  • Raised $14.78 million net of offering costs through an At-the-Market equity offering by August 2025.
  • Advanced Medicare reimbursement efforts and began setting up a new laboratory facility in 2025.

Why Cardio Diagnostics Is a Bit Different

The company uses artificial intelligence to combine genetic and epigenetic data for heart disease testing. Its products are laboratory-developed tests, which means they are created and used within certified labs. Cardio Diagnostics focuses on early detection and risk assessment, mainly for U.S. healthcare providers and employers.

Five Things You Need to Know

  • Q2 2025 revenue was $7,475, down 5.0% from Q2 2024.
  • Net loss for Q2 2025 was $1.68 million, up from $1.29 million in Q2 2024.
  • Cash balance was $7,966,500 as of June 30, 2025.
  • All revenue comes from product test sales; no international sales reported.
  • Full-time employees: 13 as of the latest report.

Bottom Line

Cardio Diagnostics has evolved by expanding its product line and digital tools. The company remains focused on heart disease risk testing, with ongoing efforts to grow its market presence.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

15

CEO

Meeshanthini V. Dogan, PhD

Website

www.cdio.ai

Headquarters

Chicago, IL 60654, US

CDIO Financials

Key Financial Metrics (TTM)

Gross Margin

-471.40%

Operating Margin

-40074.58%

Net Income Margin

-40152.50%

Return on Equity

-78.82%

Return on Capital

-84.55%

Return on Assets

-69.58%

Earnings Yield

-2.04%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.96M

Volume

4.39K

Avg. Volume

65.77K

Financials (TTM)

Gross Profit

-$78.09K

Operating Income

-$6.64M

EBITDA

-$6.27M

Operating Cash Flow

-$5.89M

Capital Expenditure

-$200.31K

Free Cash Flow

-$6.09M

Cash & ST Invst.

$7.08M

Total Debt

$533.00K

Cardio Diagnostics Performance Analysis

Cardio Diagnostics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 9505.4%
20232023-12-31USD 17,0651696.3%
20242024-12-31USD 34,890104.5%
20252025-12-31USD 14,825-57.5%
Cardio Diagnostics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30695.2%
Q32025-09-30-61.8%
Q42025-12-3124.5%
Q12026-03-31-24.6%
Cardio Diagnostics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -45.29183.0%
20232023-12-31USD -19.81-56.3%
20242024-12-31USD -9.35-52.8%
20252025-12-31USD -3.71-60.3%
Cardio Diagnostics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30-1.0%
Q42025-12-3118.4%
Q12026-03-3121.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$2.68K

+185.1%

Gross Profit

-$91.97K

-9884.3%

Gross Margin

-34.32%

N/A

Market Cap

$4.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$327.51K

N/A

Employees

15

N/A

Net Income

-$1.79M

-9.4%

EBITDA

-$1.69M

-12.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$7.08M

-27.0%

Total Debt

$533.00K

-11.9%

Accounts Receivable

$4.27K

-55.3%

Inventory

$0.00

N/A

Long Term Debt

$164.53K

-54.8%

Short Term Debt

$368.47K

+53.1%

Return on Assets

-69.58%

N/A

Return on Invested Capital

-73.21%

N/A

Free Cash Flow

-$1.56M

-8.0%

Operating Cash Flow

-$1.56M

-11.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TCRTAlaunos Therapeutics, Inc.
$2.00+0.50%
ADILAdial Pharmaceuticals, Inc.
$4.56-5.00%
CELZCreative Medical Technology Holdings, Inc.
$1.42+23.04%
RADXRadiopharm Theranostics Limited
$2.80+0.36%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$129.02+0.12%
TTDThe Trade Desk
$13.84-0.22%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$8.03+0.05%
NVDANvidia
$222.01+0.01%

Questions About CDIO

What is the current price of Cardio Diagnostics?

Cardio Diagnostics is trading at $1.74 per share.

What is the 52-week range for Cardio Diagnostics?

Over the past 52 weeks, Cardio Diagnostics has traded between $0.97 and $7.91.

How much debt does Cardio Diagnostics have?

As of the most recent reporting period, Cardio Diagnostics reported total debt of $533.00K.

How much cash does Cardio Diagnostics have on hand?

Cardio Diagnostics reported $7.08M in cash and cash equivalents in its most recent financial results.

What is Cardio Diagnostics’s dividend yield?

Cardio Diagnostics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services